




## **Patient Recruitment and Retention in Clinical Trials**

Emerging strategies in Europe, the US and Asia

By Alison Sahoo

 [Table of Contents](#)

## **Alison Sahoo**

Alison Sahoo is a pharmaceutical industry analyst with more than 10 years of experience researching the development of medicines and medical devices. She holds a B.S. in Physics from McGill University and an M.B.A. in International Business from Rutgers University.

Copyright © 2007 Business Insights Ltd  
This Management Report is published by Business Insights Ltd. All rights reserved.  
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## Patient Recruitment & Retention in Clinical Trials

<b>Executive Summary</b>	<b>10</b>	
<b>Introduction</b>	<b>10</b>	
<b>Clinical trial recruitment in the United States</b>	<b>11</b>	
<b>Clinical trial recruitment in Europe</b>	<b>12</b>	
<b>Clinical trial recruitment in Asia</b>	<b>13</b>	
<b>Regional comparison</b>	<b>14</b>	
<b>Chapter 1</b>	<b>Introduction</b>	<b>18</b>
<b>Summary</b>		<b>18</b>
<b>The global environment for drug development</b>		<b>19</b>
More sophisticated science		19
More complicated disease targets		21
Heightened regulatory scrutiny		21
Other imperatives requiring greater drug safety		23
Adverse drug reactions		23
DTC Advertising		23
Internet Sourcing of Drugs		25
Rising lawsuits		26
<b>R&amp;D cost pressures</b>		<b>27</b>
Spending on drug development		27
R&D Productivity		28
Outsourced R&D		30
<b>The importance of clinical trial recruitment</b>		<b>31</b>
Growing number and size of clinical trials		31
The cost of patient recruitment delays		32
<b>Emerging recruitment strategies</b>		<b>33</b>
Web-based registries		33
Study-specific websites		35
Specialized publications		36
Proactive targeting measures		36
<b>Conversion and retention</b>		<b>37</b>
<b>Ethical issues</b>		<b>38</b>

Declaration of Helsinki	38
Clinician's finder fees	39
Participant disclosures	40
<b>Conclusions</b>	<b>41</b>
<b>Chapter 2</b>	<b>Clinical trial recruitment in the US 44</b>
<b>Summary</b>	<b>44</b>
<b>The clinical trial process</b>	<b>45</b>
Contract research	47
<b>Recruitment requirements</b>	<b>48</b>
Recruitment issues	49
Conversion and retention	49
Incentives	50
Regulations	51
<b>Current patient recruitment practices</b>	<b>53</b>
Consumer attitudes towards clinical trials	54
Online recruitment	57
Case study: BBK Worldwide	59
National networks	60
Electronic alerts in computerized medical records	61
Offshore clinical testing	62
<b>New initiatives and best practices</b>	<b>63</b>
Expansion of early testing	64
Including women in clinical trials	64
Usage of prisoners	66
Streamlining of multiple sites	67
<b>Interactive voice response (IVR)</b>	<b>68</b>
<b>Current physician recruitment practices</b>	<b>69</b>
Physician attitudes towards clinical trials	70
Online recruitment	70
Data management	71
<b>Clinical trial information</b>	<b>72</b>
Government sources	72
Other sources	73
<b>Conclusions</b>	<b>74</b>
<b>Chapter 3</b>	<b>Clinical trial recruitment in Europe 76</b>
<b>Summary</b>	<b>76</b>
<b>The clinical trial process</b>	<b>77</b>

<b>Contract research</b>	<b>80</b>
Eastern Europe	81
CRO developments in Eastern Europe	84
Other parts of Europe	85
<b>Recruitment requirements</b>	<b>85</b>
Recruitment issues	85
Conversion and retention	86
Incentives	87
Regulations	87
<b>Current patient recruitment practices</b>	<b>90</b>
Consumer attitudes towards clinical trials	90
Online recruitment	92
Case study: Richmond Pharmacology	93
<b>New initiatives and best practices</b>	<b>94</b>
Bulgaria and Romania	94
Including women in clinical trials	95
<b>Current physician recruitment practices</b>	<b>96</b>
Physician attitudes towards clinical trials	96
Online recruitment	97
<b>Clinical trial information</b>	<b>97</b>
Government sources	97
Other sources	98
<b>Conclusions</b>	<b>99</b>

## **Chapter 4                      Clinical trial recruitment in Asia                      102**

<b>Summary</b>	<b>102</b>
<b>The clinical trial process</b>	<b>103</b>
Contract research	104
<b>India</b>	<b>106</b>
Patent issues	109
CRO developments in India	109
<b>China</b>	<b>110</b>
Patent Issues in China	113
CRO developments in China	114
<b>Recruitment requirements</b>	<b>115</b>
Recruitment issues	115
Conversion and retention	115
Incentives	116
<b>Regulations</b>	<b>117</b>
Japan	117
China	118
India	118
<b>Current patient recruitment practices</b>	<b>120</b>

Consumer attitudes towards clinical trials	120
Online recruitment	121
<b>New initiatives and best practices</b>	<b>122</b>
Big pharma clinical trial centers	122
Case study: Shanghai	122
Ethical issues	123
Case study: Chiltern International	124
<b>Current physician recruitment practices</b>	<b>125</b>
Physician attitudes towards clinical trials	125
Online recruitment	126
Clinical trial information	126
Government sources	127
Other sources	127
<b>Conclusions</b>	<b>128</b>

## **Chapter 5                      Regional comparison                      130**

<b>Summary</b>	<b>130</b>
<b>Consumer attitudes towards clinical trials</b>	<b>131</b>
Demand for access to information	135
Impressions of currently available clinical trial information	136
<b>Physician attitudes towards clinical trials</b>	<b>138</b>
<b>Growth drivers</b>	<b>142</b>
Regional impact on patient recruitment	143
Regional impact on physician recruitment	144
<b>Conclusions</b>	<b>146</b>
<b>Index</b>	<b>148</b>

# List of Figures

Figure 1.1:	Adverse Drug Events, 1995 - 2006	24
Figure 1.2:	NME Approvals vs. R&D Spend (1980 – 2006)	29
Figure 1.3:	R&D Spend per NME Approval by Year (1990 – 2005)	30
Figure 3.1:	Factors Impacting Study Participation in Europe	91
Figure 4.1:	Relative importance of Asian pharmaceutical markets, 2007	103
Figure 4.2:	Japanese drug approval process, 2007	105
Figure 5.1:	Clinical Study Participation in U.S., EU and Japan, 2005 vs. 2004	131
Figure 5.2:	How clinical study participants were enrolled in trials	132
Figure 5.3:	Consumers who have looked for health information for themselves or their children within the past 6 months	133
Figure 5.4:	Factors Impacting Patient Study Participation in U.S., EU and Japan	134
Figure 5.5:	Consumers who would return regularly to a website that included clinical trial results	135
Figure 5.6:	Main obstacles for consumers in accessing clinical trial information online	136
Figure 5.7:	Likelihood of returning regularly to a clinical trial website by feature	137
Figure 5.8:	Physicians participating in clinical trials, current vs. planned	139
Figure 5.9:	How clinical study physicians were enrolled in trials	140
Figure 5.10:	Factors Impacting Physician Study Participation in U.S., EU and Japan	141
Figure 5.11:	How clinical study physicians were enrolled in trials	144
Figure 5.12:	Physician technology utilization in clinical trials by region	145
Figure 5.13:	Physician access to technology by region	146

# List of Tables

Table 1.1:	Recent US drug recalls, 2000 - 2006	22
Table 1.2:	US R&D Spend per NME Approved, 1990 - 2005	29
Table 2.3:	Patient recruitment requirements by clinical trials phase	49
Table 2.4:	US clinical trial recruitment websites	57
Table 2.5:	Global operations of leading CROs	63
Table 3.6:	Eastern European operations of leading CROs	84
Table 4.7:	US FDA new drug application data generated from India	107
Table 5.8:	Region-specific growth drivers and restraints for clinical trial activity, 2007	143

